Shareholder information
Important information:
Our Company’s registered office is Mereside, Alderley Park, Alderley Edge, Cheshire, UK SK10 4TG
You can contact the Company by emailing us at info@bivictrix.com
This website will be updated so you can stay informed of Company news.
Matched Bargain Facility
Investor Information
The Company’s Ordinary Shares have been admitted onto the J P Jenkins Ltd liquidity venue for private securities, under the ticker: BVX JP Jenkins is the UK’s established platform for unquoted companies which enables shareholders and prospective investors to buy and sell shares through a UK stockbroker. The indicative price and transaction history of the company is available on J P Jenkins’s website at: www.jpjenkins.com. How to trade? To buy and sell shares in this company via JP Jenkins, you will need to use a regulated UK stockbroker. Over 40 UK brokers regularly trade and are set up to electronically deal on JP Jenkins. When buying or selling shares, please note there is as 1.5% trading fee (with a minimum charge of £25) (*additional fees may apply). Please note, when purchasing shares Stamp Duty Reserve Tax (“SDRT”) may be applicable. For more information, please call +44 (0) 20 7469 0937. If you are based overseas and are interested in participating then you can also contact JP Jenkins directly by emailing info@jpjenkins.comAIM Delisting
On 12 August 2024, BiVictriX Therapeutics plc (the “Company” or “BiVictriX”) announced the proposed cancellation of admission of its ordinary shares to trading on AIM, re-registration as a private limited company and adoption of new articles of association (the “Proposed Cancellation and Re-registration”).
A copy of the RNS announcement can be found here.
A copy of the circular can be found here.
On 29 August 2024, the Company announced that, at the general meeting of the Company held on 29 August 2024, all resolutions put to the Company’s shareholders with respect to the Proposed Cancellation and Re-Registration were duly passed and the admission of the Company’s ordinary shares to trading on AIM would be cancelled.
A copy of the RNS announcement can be found here.
As announced, the last day of trading in the Company’s ordinary shares on AIM was 10 September 2024 and the Company’s ordinary shares were cancelled from admission to trading on AIM effective 7:00 a.m. on 11 September 2024.
